Payment overview · 2025
General Payments
$865.44
46 reported records · 16 companies
Healthcare provider profile · identity verified
Steve F Springer, MD
Allopathic & Osteopathic Physicians|Family Medicine · LAKE CHARLES, LA · NPI 1477538619
Verified facts
What the public records show
CMS Open Payments records show Steve F Springer, MD received $865.44 in general payments during 2025 across 46 reported records.
GlaxoSmithKline, LLC. accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $143.02 | 16.5% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.28 | 16.3% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $107.96 | 12.5% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $82.30 | 9.5% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $82.24 | 9.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.87 | 7.2% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.77 | 5.5% | 3 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $44.48 | 5.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.15 | 3.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.74 | 2.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.41 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.99 | 2.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.67 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.04 | 1.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.63 | 1.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.89 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $865.44 | 46 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $143.02 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $104.92 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $95.36 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $82.30 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $66.26 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.77 | 3 | 2025 |
Source payment records
|
|||||
| GRAFIX Normalized: grafix |
Biological | Smith+Nephew, Inc. | $44.48 | 1 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $44.48 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.70 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $39.19 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.15 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.74 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 104 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 145 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 270 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 33 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
199 | 52 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 37 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
145 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
270 | 64 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 28 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
104 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 771 | 239 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 635 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 586 | 176 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 447 | 146 |
| Metformin Hcl Er | Metformin Hcl | 420 | 127 |
| Gabapentin | Gabapentin | 384 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 112 |
| Omeprazole | Omeprazole | 328 | 105 |
| Losartan Potassium | Losartan Potassium | 325 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 318 | 99 |
| Paroxetine Hcl | Paroxetine Hcl | 284 | 64 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 283 | 75 |
| Alprazolam | Alprazolam | 280 | 51 |
| Mounjaro | Tirzepatide | 270 | 64 |
| Trazodone Hcl | Trazodone Hcl | 269 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 240 | 87 |
| Lisinopril | Lisinopril | 232 | 73 |
| Montelukast Sodium | Montelukast Sodium | 230 | 74 |
| Farxiga | Dapagliflozin Propanediol | 199 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 64 |
| Furosemide | Furosemide | 187 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 68 |
| Celecoxib | Celecoxib | 175 | 106 |
| Clopidogrel | Clopidogrel Bisulfate | 166 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 165 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 155 | 21 |
| Allopurinol | Allopurinol | 154 | 43 |
| Jardiance | Empagliflozin | 145 | 37 |
| Azithromycin | Azithromycin | 139 | 114 |
| Zolpidem Tartrate | Zolpidem Tartrate | 136 | 28 |
| Meloxicam | Meloxicam | 130 | 48 |
| Clonazepam | Clonazepam | 128 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 123 | 35 |
| Sertraline Hcl | Sertraline Hcl | 117 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 116 | 36 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 115 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 24 |
| Metformin Hcl | Metformin Hcl | 106 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 38 |
| Tramadol Hcl | Tramadol Hcl | 105 | 25 |
| Eliquis | Apixaban | 104 | 25 |
| Ozempic | Semaglutide | 104 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 34 |
| Pregabalin | Pregabalin | 96 | 23 |
| Carvedilol | Carvedilol | 95 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 95 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 90 | 18 |
| Buspirone Hcl | Buspirone Hcl | 85 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 81 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 23 |
| Donepezil Hcl | Donepezil Hcl | 80 | 30 |
| Finasteride | Finasteride | 79 | 17 |
| Januvia | Sitagliptin Phosphate | 76 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 76 | 59 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 18 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 68 | 25 |
| Potassium Chloride | Potassium Chloride | 67 | 18 |
| Valsartan | Valsartan | 67 | 28 |
| Simvastatin | Simvastatin | 65 | 21 |
| Mirtazapine | Mirtazapine | 64 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 20 |
| Meclizine Hcl | Meclizine Hcl | 62 | 20 |
| Labetalol Hcl | Labetalol Hcl | 61 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 20 |
| Nifedipine Er | Nifedipine | 58 | 16 |
| Glimepiride | Glimepiride | 55 | 20 |
| Trulicity | Dulaglutide | 55 | 14 |
| Fluconazole | Fluconazole | 54 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 18 |
| Atenolol | Atenolol | 51 | 13 |
| Estradiol | Estradiol | 50 | 19 |
| Prednisone | Prednisone | 50 | 42 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 15 |
| Clonidine Hcl | Clonidine Hcl | 47 | 15 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Bupropion Xl | Bupropion Hcl | 45 | 12 |
| Ezetimibe | Ezetimibe | 45 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 38 |
| Topiramate | Topiramate | 42 | suppressed |
| Spironolactone | Spironolactone | 41 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 40 | 22 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 11 |
| Memantine Hcl Er | Memantine Hcl | 35 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 35 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 12 |
| Levetiracetam | Levetiracetam | 33 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 32 |
| Synthroid | Levothyroxine Sodium | 33 | 11 |
| Baclofen | Baclofen | 32 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | 20 |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 24 |
| Famotidine | Famotidine | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 21 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 13 |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Risperidone | Risperidone | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 17 |
| Candesartan Cilexetil | Candesartan Cilexetil | 17 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Methylprednisolone | Methylprednisolone | 15 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $865.44 · 46 records | GlaxoSmithKline, LLC. | BREZTRI, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GRAFIX, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, STRAVIX, SYNTHROID, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error